Pivot3 to Acquire NexGen Storage to Shift the Hyper-Converged Market toward More Dynamic Solutions
Pivot3, a pioneer and innovator in the development of hyper-converged infrastructure (HCI), today announced that it will acquire NexGen Storage, a privately held leading provider of hybrid storage appliances, dynamic all-flash arrays and Quality of Service (QoS) capabilities. By adding NexGen’s portfolio of products, Pivot3 will deliver the industry's most complete set of dynamic hyper-converged solutions. For the first time ever, enterprise and mid-market companies will have access to a suite of solutions that will allow them to apply the right infrastructure and priority to each workload, application or business service according to business value.
By adding NexGen’s strengths in accelerated all-flash and hybrid storage, Pivot3 is uniquely expanding the traditional notion of hyper-convergence. Now, customers have complete implementation flexibility and QoS management, so IT no longer has to overprovision for peak workloads, but instead can use just-in-time dynamic provisioning of resources and scale as the business grows. Pivot3 intends to market and enhance all current and planned NexGen products.
“Everyone talks about the need for agility in terms of business needs, but in hyper-convergence, workload utilization and performance have been gating factors to expansion beyond the usual initial use cases,” said Ron Nash, CEO of Pivot3. “With the addition of NexGen’s capabilities, Pivot3 is now the only company in the market that broadly and deeply addresses this central data center challenge with a solution that allows IT to prioritize application performance based on business priority. We believe this agility is critical as customers move from legacy data centers to a software-defined data center that effortlessly handles a heterogeneous set of workloads. We welcome the NexGen customers, partners and team to Pivot3.”
Unlike other storage arrays and hyper-converged systems that treat all data the same, NexGen’s dynamic QoS governs performance targets, input/output (I/O) prioritization and data placement, allowing customers to meet business service-level agreements. For example, an organization serving the healthcare market can prioritize mission-critical hospital system applications over the internal Microsoft Exchange server, preventing a surge in employee email downloads from interrupting life-or-death health care system operations.
“We categorize all of our applications as mission-critical, business-critical or non-critical,” said Michael Frank, manager IT services group, NCS Credit. “We need our systems to be able to recognize that not all applications are created equal and to process them appropriately and differentially.”
“Not all data should be treated the same; the growing momentum of the Internet of Things (IoT), together with ever-increasing user-expectations and application-demands, means there is a pressing need for HCI platforms that are optimally built to manage the onslaught of disparate data,” said Mark Peters, practice director and senior analyst at Enterprise Strategy Group (ESG). “Pivot3’s new approach offers precisely this with its hyper-converged solution-suite; it includes compelling differentiations which enable it to support more extensive and expansive use cases by delivering increased and optimized value from the data it manages.”
Dynamic hyper-convergence provides enterprises with a practical and proven path to extend the economics and simplicity of HCI to all business services, effectively enabling the first generation of software-defined data centers. Pivot3 provides HCI, hybrid and all-flash storage in appliance and blade form factors. Their patented Scalar Erasure Coding gives their HCI technology the ability to yield up to 94 percent usable storage, and their all-flash HCI appliances are specifically designed to provide maximum input/output operations per second (IOPS) for high-performance applications. Combined with NexGen’s proven QoS and dynamic provisioning capabilities, high-performance hybrid storage and all-flash form factors, Pivot3 now provides the most extensive suite of HCI solutions available in the market.
“We’re proud of our rich history and our reputation as a leader in new technology storage products, and we see enormous synergies in bringing together these two innovative businesses,” said John Spiers, founder and CEO of NexGen. “The pedigrees of our teams in the storage and high-performance computing markets are unparalleled in the industry. Combining these powerful teams and innovative solutions gives our customers and partners an incredible advantage in their respective markets.”
Pivot3 executed a definitive agreement to acquire NexGen following the unanimous approval of the Boards of Directors of Pivot3 and NexGen. The transaction is expected to close in February 2016.
Pivot3 is the world’s leading provider of dynamic hyper-converged solutions. Pivot3’s patented solutions dramatically improve data center simplicity and economics by increasing scale-out performance, driving down complexity and cost, saving an extraordinary amount of disk and physical space and ensuring fault tolerance. With Pivot3’s unique Quality of Service and Virtualization Management capabilities, customers are able to prioritize data and application performance based on business value. Today, Pivot3 has more than 2,000 customers around the world deploying more than 16,000 globally hyper-converged infrastructures in multiple industries such as video surveillance, healthcare, government, transportation, entertainment, education, gaming and retail. Join us on LinkedIn, follow us on Facebook or Twitter (@Pivot3Inc) or visit us at http://pivot3.com. The company has won numerous awards and was most recently featured by CRN in their top 50 Virtualization list. To learn more about Pivot3, visit http://www.pivot3.com.
Allison Francis, 972-235-3439
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom